326 related articles for article (PubMed ID: 24089294)
1. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Gasche D; Ulle T; Meier B; Greiner RA
Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294
[TBL] [Abstract][Full Text] [Related]
2. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Chin CT; Mellstrom C; Chua TS; Matchar DB
Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Coleman CI; Limone BL
Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
[TBL] [Abstract][Full Text] [Related]
4. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Theidel U; Asseburg C; Giannitsis E; Katus H
Clin Res Cardiol; 2013 Jun; 102(6):447-58. PubMed ID: 23474908
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Nikolic E; Janzon M; Hauch O; Wallentin L; Henriksson M;
Eur Heart J; 2013 Jan; 34(3):220-8. PubMed ID: 22719022
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
[TBL] [Abstract][Full Text] [Related]
8. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.
Henriksson M; Nikolic E; Ohna A; Wallentin L; Janzon M
Scand Cardiovasc J; 2014 Jun; 48(3):138-47. PubMed ID: 24650118
[TBL] [Abstract][Full Text] [Related]
10. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
Cowper PA; Pan W; Anstrom KJ; Kaul P; Wallentin L; Davidson-Ray L; Nikolic E; Janzon M; Levin LÅ; Cannon CP; Harrington RA; Mark DB
J Am Coll Cardiol; 2015 Feb; 65(5):465-76. PubMed ID: 25660925
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
[TBL] [Abstract][Full Text] [Related]
12. Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
Janzon M; James S; Cannon CP; Storey RF; Mellström C; Nicolau JC; Wallentin L; Henriksson M
Heart; 2015 Jan; 101(2):119-25. PubMed ID: 25227704
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y
Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ
Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
[TBL] [Abstract][Full Text] [Related]
15. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Okere AN; Ezendu K; Berthe A; Diaby V
J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
[TBL] [Abstract][Full Text] [Related]
16. Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile.
De la Puente C; Vallejos C; Bustos L; Zaror C; Velasquez M; Lanas F
J Clin Epidemiol; 2017 Jun; 86():117-124. PubMed ID: 27989953
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
18. Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
Coleman CI; Limone BL
Thromb Haemost; 2014 Jan; 111(1):103-10. PubMed ID: 24136466
[TBL] [Abstract][Full Text] [Related]
19. [Budget impact analysis of antiplatelet therapy with ticagrelor and clopidogrel in patients with acute coronary syndrome after coronary artery bypass surgery].
Zyryanov SK; Belousov DY; Afanasyeva EV; Dumchenko EV
Ter Arkh; 2016; 88(9):39-49. PubMed ID: 27735912
[TBL] [Abstract][Full Text] [Related]
20. [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Molina-Cuadrado E; Mateo-Carrasco H; Nieto-Guindo P; Rodríguez-Gómez P
Farm Hosp; 2014 Jul; 38(4):266-75. PubMed ID: 25137159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
